KMT2A and acute lymphoblastic leukemia: Ou et al. further characterized these alterations in a large AYA/adult cohort, identifying mutations in TET2, KMT2A, and PHF6 in 31.4% of B-ALL patients and associating them with poorer outcomes, particularly in cytogenetically normal cases [24].